Tetraphase Pharmaceuticals Inc

Most Recent

  • uploads///pills _
    Company & Industry Overviews

    Analysts’ Ratings for Sarepta Therapeutics and Peers in April

    Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating.

    By Kenneth Smith
  • uploads///rawpixel com  unsplash
    Company & Industry Overviews

    How Analysts View Tetraphase Pharmaceuticals in April 2018

    Of eight analysts tracking Tetraphase Pharmaceuticals, one analyst rated it as a “strong buy,” and six analysts gave it a “buy” rating.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.